Hepatotoxic effect of a combination of pyrazinamide with isoniazid and rifampicin
Hepatotoxic effect of a combination of pyrazinamide with isoniazid and rifampicin
复制标题
DOI：
--
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
Slivka IuI;Klimniuk Ev;T. Oe
中科院分区：
文献类型：
--
作者：
Slivka IuI;Klimniuk Ev;T. Oe
对大鼠的实验表明，将动物暴露于1.5 g/kg剂量的吡嗪酰胺14天，可诱导胆固醇生成明显紊乱，并降低肝脏中还原型谷胱甘肽水平。当吡嗪酰胺与异烟肼或利福平联合使用时，除了胆汁生成障碍和谷胱甘肽水平降低外，还观察到血清中天冬氨酸和丙氨酸转氨酶活性显著增加，并诱导肝脏脂质过氧化。联用阿昔酰胺、异烟肼和利福平诱导的肝脏疾病与吡嗪酰胺联合异烟肼或利福平观察到的肝脏疾病无显著差异。
: Experiments on rats showed that 14-day exposure of the animals to pyrazinamide in a dose of 1.5 g/kg induced marked disorders in cholopoiesis and lowering of the reduced glutathion levels in the liver. When pyrazinamide was used in combination with isoniazid or rifampicin a marked increase in the activity of aspartate and alanine aminotransferases in blood serum and induction of lipid peroxidation in the liver were observed in addition to the disorders in cholopoiesis and lowering of the reduced glutathion levels. Combined use of pyraxinamide, isoniazid and rifampicin induced disorders in the liver state not differing significantly from those observed with using pyrazinamide in combination with isoniazid or rifampicin.